POS1255 REACTOGENICITY OF SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASE

Background: Patients with autoimmune disease often require immunosuppressive medications that may increase their risk of developing severe illness from COVID-19. The importance immunization in this population is particularly high. While the studied vaccines show efficacy general population, nothing known regarding immune response or safety profile patients and those taking immunomodulatory medications. Objectives: To assess degree adverse events SARS-CoV-2 inflammatory disease. Methods: This study part a larger prospective observational examining immunogenicity vaccine immune-mediated diseases Adults an scheduled to receive either Pfizer Moderna SARS-COV-2 were enrolled study. Subjects participated 3 visits (pre-vaccine, dose 1 (D1) 2 (D2)) where blood, for immunologic assays, clinical data collected. Assessments (AE), including local systemic symptoms validated AE severity solicited within 7 days receiving each dose. Results: date, 70 have been enrolled. Demographic characteristics are shown Table 1. Distribution current included prednisone 18.6%, conventional synthetic DMARD 55.7%, targeted 4.3%, biologic 68.5%. Almost all participants experienced event following vaccination (D1 96%, D2 100%). Following D1 AEs generally mild (76.5%) whereas large portion moderate (47.8%) (30.5%). Injection site pain was most common both doses followed by arthralgias 21.6%, 78.2%), fever 70%) fatigue 65.2%) (Figure 1). Figure Solicited Local Systemic Adverse Events. Percentage who had endorsed first second Vaccine. ‘Other’ chills, blurry vision, brain fog dizziness. Conclusion: experience significant burden frequency appearing greater than reported results trials. Several such as fever, can also be commonly seen rheumatologic diseases, mimicking flares. crucial demonstrates understanding patient better inform possible expected side effects further management future. Clinical Characteristics Participants Parameter N (% ) N=70 Age [years], mean (SD) group 48.3 ± 16.4 < 65 53 (75.7) 65+ 17 (24.3) Gender Female 48 (68.6) Male 20 (38.5) Other (2.9) Race White 47 (67.1) Asian 14 (20.0) Hispanic 8 (11.4) Black (1.4) BMI [kg/m2], 25.0 5.4 Immunologic Diagnosis Rheumatoid Arthritis 21 (30.0) Spondyloarthritis* Lupus Erythematous Connective Tissue Disease, ‡ 12 (17.1) Vasculitis (4.2) Inflammatory Bowel Disease (10.0) Autoinflammatory Syndrome 5 (7.1) Multiple Sclerosis IgG4 Related Duration 9.0 Medications Prednisone 13 (18.6) DMARDs Hydroxychloroquine 16 (22.9) Methotrexate 15 (21.4) Sulfasalazine 6 (8.6) Tofacitinib (4.3) Azathioprine Biologics TNF inhibitor 33 (47.1) Rituximab (10) Abatacept IL-23 * Spondyloarthritis includes Axial Psoriatic Arthritis. scleroderma, Sjogren’s syndrome, polymyositis, UCTD. Disclosure Interests: Monica Yang: None declared, Patti Katz: Diana Paez: Alexander Carvidi: Mehrdad Matloubian: Mary Nakamura: Lianne S. Gensler Consultant of: AbbVie, Eli Lilly, Gilead, GSK, Novartis, Grant/research support from: UCB